Your browser doesn't support javascript.
loading
Mechanistic understanding of the combined immunodeficiency in complete human CARD11 deficiency.
Lu, Henry Y; Sharma, Mehul; Sharma, Ashish A; Lacson, Atilano; Szpurko, Ashley; Luider, Joanne; Dharmani-Khan, Poonam; Shameli, Afshin; Bell, Peter A; Guilcher, Gregory M T; Lewis, Victor A; Vasquez, Marta Rojas; Desai, Sunil; McGonigle, Lyle; Murguia-Favela, Luis; Wright, Nicola A M; Sergi, Consolato; Wine, Eytan; Overall, Christopher M; Suresh, Sneha; Turvey, Stuart E.
Afiliación
  • Lu HY; Department of Pediatrics, British Columbia Children's Hospital, The University of British Columbia, Vancouver, British Columbia, Canada; Experimental Medicine Program, Faculty of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada.
  • Sharma M; Department of Pediatrics, British Columbia Children's Hospital, The University of British Columbia, Vancouver, British Columbia, Canada; Experimental Medicine Program, Faculty of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada.
  • Sharma AA; Department of Pathology, Case Western Reserve University, Cleveland, Ohio; Department of Pathology, Emory University, Atlanta, Ga.
  • Lacson A; Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada.
  • Szpurko A; Section of Oncology/Bone Marrow Therapy, Departments of Oncology and Pediatrics, Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada.
  • Luider J; Department of Pathology and Laboratory Medicine, University of Calgary, Alberta Precision Laboratories, Calgary, Alberta, Canada.
  • Dharmani-Khan P; Department of Pathology and Laboratory Medicine, University of Calgary, Alberta Precision Laboratories, Calgary, Alberta, Canada.
  • Shameli A; Department of Pathology and Laboratory Medicine, University of Calgary, Alberta Precision Laboratories, Calgary, Alberta, Canada.
  • Bell PA; Centre for Blood Research, The University of British Columbia, Vancouver, British Columbia, Canada; Department of Oral Biological and Medical Sciences, Faculty of Dentistry, The University of British Columbia, Vancouver, British Columbia, Canada.
  • Guilcher GMT; Section of Oncology/Bone Marrow Therapy, Departments of Oncology and Pediatrics, Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada.
  • Lewis VA; Section of Oncology/Bone Marrow Therapy, Departments of Oncology and Pediatrics, Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada.
  • Vasquez MR; Department of Pediatrics, Division of Immunology, Hematology, Oncology and Palliative Care (iHOPE), University of Alberta, Edmonton, Alberta, Canada.
  • Desai S; Department of Pediatrics, Division of Immunology, Hematology, Oncology and Palliative Care (iHOPE), University of Alberta, Edmonton, Alberta, Canada.
  • McGonigle L; Department of Pediatrics, Division of General and Community Pediatrics, University of Alberta, Edmonton, Alberta, Canada.
  • Murguia-Favela L; Section of Pediatric Hematology-Immunology, Department of Pediatrics, Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada.
  • Wright NAM; Section of Pediatric Hematology-Immunology, Department of Pediatrics, Alberta Children's Hospital, University of Calgary, Calgary, Alberta, Canada.
  • Sergi C; Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada.
  • Wine E; Division of Pediatric Gastroenterology and Nutrition, Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada.
  • Overall CM; Centre for Blood Research, The University of British Columbia, Vancouver, British Columbia, Canada; Department of Oral Biological and Medical Sciences, Faculty of Dentistry, The University of British Columbia, Vancouver, British Columbia, Canada.
  • Suresh S; Department of Pediatrics, Division of Immunology, Hematology, Oncology and Palliative Care (iHOPE), University of Alberta, Edmonton, Alberta, Canada.
  • Turvey SE; Department of Pediatrics, British Columbia Children's Hospital, The University of British Columbia, Vancouver, British Columbia, Canada; Experimental Medicine Program, Faculty of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: sturvey@cw.bc.ca.
J Allergy Clin Immunol ; 148(6): 1559-1574.e13, 2021 12.
Article en En | MEDLINE | ID: mdl-33872653
BACKGROUND: Germline pathogenic variants impairing the caspase recruitment domain family member 11 (CARD11)-B cell chronic lymphocytic leukemia/lymphoma 10 (BCL10)-MALT1 paracaspase (MALT1) (CBM) complex are associated with diverse human diseases including combined immunodeficiency (CID), atopy, and lymphoproliferation. However, the impact of CARD11 deficiency on human B-cell development, signaling, and function is incompletely understood. OBJECTIVES: This study sought to determine the cellular, immunological, and biochemical basis of disease for 2 unrelated patients who presented with profound CID associated with viral and fungal respiratory infections, interstitial lung disease, and severe colitis. METHODS: Patients underwent next-generation sequencing, immunophenotyping by flow cytometry, signaling assays by immunoblot, and transcriptome profiling by RNA-sequencing. RESULTS: Both patients carried identical novel pathogenic biallelic loss-of-function variants in CARD11 (c.2509C>T; p.Arg837∗) leading to undetectable protein expression. This variant prevented CBM complex formation, severely impairing the activation of nuclear factor-κB, c-Jun N-terminal kinase, and MALT1 paracaspase activity in B and T cells. This functional defect resulted in a developmental block in B cells at the naive and type 1 transitional B-cell stage and impaired circulating T follicular helper cell (cTFH) development, which was associated with impaired antibody responses and absent germinal center structures on lymph node histology. Transcriptomics indicated that CARD11-dependent signaling is essential for immune signaling pathways involved in the development of these cells. Both patients underwent hematopoietic stem cell transplantations, which led to functional normalization. CONCLUSIONS: Complete human CARD11 deficiency causes profound CID by impairing naive/type 1 B-cell and cTFH cell development and abolishing activation of MALT1 paracaspase, NF-κB, and JNK activity. Hematopoietic stem cell transplantation functionally restores impaired signaling pathways.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Linfocitos T Colaboradores-Inductores / Trasplante de Células Madre Hematopoyéticas / Centro Germinal / Proteínas Adaptadoras de Señalización CARD / Células Precursoras de Linfocitos B / Enfermedades de Inmunodeficiencia Primaria / Guanilato Ciclasa / Mutación Límite: Adolescent / Child / Humans / Infant / Male Idioma: En Revista: J Allergy Clin Immunol Año: 2021 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Linfocitos T Colaboradores-Inductores / Trasplante de Células Madre Hematopoyéticas / Centro Germinal / Proteínas Adaptadoras de Señalización CARD / Células Precursoras de Linfocitos B / Enfermedades de Inmunodeficiencia Primaria / Guanilato Ciclasa / Mutación Límite: Adolescent / Child / Humans / Infant / Male Idioma: En Revista: J Allergy Clin Immunol Año: 2021 Tipo del documento: Article País de afiliación: Canadá